Startup compensation is often an opaque and awkward topic for first-time academic founders. How much equity do I receive? My CEO? The PI(s)? Other co-founders? How will my choices affect future compensation?
Since its inception in 2009, OUP’s mission has been to foster deep partnerships with universities with three goals in mind: 1) to invest in their spinouts, 2) to help improve technology transfer effectiveness, and 3) to help improve research commercialization by connecting university startups to our network for funding and recruitment opportunities. Please join OUP for an upcoming webinar where we dive into specifics around how we work with our academic partners and continually work to achieve our mission.
Academics looking to maximize the impact of their research shouldn’t consider commercialization a Faustian bargain, trading open publication and monetary returns. Open-source software can be a successful strategy towards both impact and income.
Join David Dorsey and John Lee of Osage University Partners as they discuss why open source provides substantial advantages for software startups and why it has become the de facto method for deploying and commercializing software.
Therapeutics remain the primary focus for life science venture investments. As we all know, pre-clinical development of therapeutics is complicated, time consuming, and capital intensive. In the early stages of development, multiple aspects of a therapeutic product need to be optimized to enhance its drug-like properties. However, given the limited time and resources in the academic setting, what aspects of development should inventors focus on? Before diving into drug development, inventors should ask themselves: What is feasible in an academic setting? What is valued more by the investors? Should it be performed in-house or be out-sourced? How much would it cost?
We’re almost halfway through 2018, which means it is once again time for OUP’s annual financing trends webinar. Which sectors have had the greatest investment and which are facing funding challenges? How do these trends apply to advancing academic technologies? What does the beginning of 2018 imply for the rest of the year and what lies over the horizon?